Lucrecia Sta Ana, MD
Colon & Rectal Surgery · Katy, TXNPI 1760633176
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $11,056 of the $12,747 with a category attached, or 86.7%. AbbVie accounts for 81.8% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2023 at $2,701 and has fallen 64.6% since, to $955 in 2025.
Across 126 payments — averaging $101.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$10K
- Stryker$446
- Davol Inc.$435
- Myriad Genetic Laboratories, Inc.$327
- Baxter Healthcare$319
- Intuitive Surgical$296
- plus $497 from 8 others
What the payments were for
- Travel & lodging$1,69113%
- Food & beverage$11,05687%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 84 | $10,427 |
| Stryker | 3 | $446 |
| Davol Inc. | 6 | $435 |
| Myriad Genetic Laboratories, Inc. | 16 | $327 |
| Baxter Healthcare | 3 | $319 |
| Intuitive Surgical | 4 | $296 |
| TELA Bio, Inc. | 3 | $229 |
| Innocoll Pharmaceuticals Limited | 1 | $147 |
| Hologic Sales And Service, LLC | 1 | $35 |
| Mimedx Group, Inc. | 1 | $23 |
| Pacira Pharmaceuticals Incorporated | 1 | $19 |
| Solventum Corporation | 1 | $17 |
| Shire North American Group Inc | 1 | $15 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,747 in reported general payments places this provider in the 70th percentile of 200 colon & rectal surgery providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 17 | $223 |
| Tramadol Hcl | 22 | $93 |
| Ibuprofen | 18 | $54 |
Paid to pharmacies, not to this prescriber.
Other colon & rectal surgery in Katy
- Thiru LakshmanAustin$756K
- Diego Marines CopadoHouston$462K
- Bidhan DasSugar Land$350K
- Christopher de JesusSan Antonio$201K
- Farshid AraghizadehFort Worth$181K
- Jefferson HurleyIrving$163K
- Erik AskenasyHouston$142K
- Eric HaasHouston$140K
- Robert JacobsonDallas$125K
- Theodoros VoloyiannisHouston$100K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.